Analyst consensus rating

AgomAb Therapeutics Analyst Rating: Strong Buy

Direct answer

AgomAb Therapeutics's consensus rating is Strong Buy.

6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $37.67.
Forecast evidence checked November 17, 2026.

Get free AgomAb Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$5.97
Average price target
$37.67
High price target
$60.00
Low price target
$28.00
Low target gap
+369%
Target upside
+530.9%
High target gap
+905%
Target range width
536%
Consensus rating
Strong Buy
Analysts
6
Evidence date
November 17, 2026
Valid through
November 24, 2026

Read the frequently asked questions.

What is the analyst consensus rating for AgomAb Therapeutics?

AgomAb Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $37.67.

How far are AgomAb Therapeutics's low and high targets from the recorded price?

The low target implies +369%, while the high target implies +905%.

How many analysts are included in AgomAb Therapeutics's consensus?

The verified consensus includes 6 analysts.

How is AgomAb Therapeutics's target upside or downside calculated?

The average target of $37.67 is divided by the recorded price of $5.97, then one is subtracted to produce +530.9%. This does not guarantee a future return.

When was AgomAb Therapeutics's analyst forecast verified?

The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.